Galantamin etkileşimleri

Pyridostigmine bromide extended-release tablets are contraindicated in patients with: Mechanical intestinal or urinary obstruction Known hypersensitivity to pyridostigmine or other anticholinesterase agents Mechanical intestinal or urinary obstruction. (Piridostigmin etiketi, Kontrendikasyonlar)

Therefore, patients should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those with an increased risk for developing ulcers, e.g., those with a history of ulcer disease or patients using concurrent nonsteroidal anti-inflammatory drugs (NSAIDS). (Galantamin etiketi, Uyarılar ve önlemler)

Therefore, patients should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those with an increased risk for developing ulcers, e.g., those with a history of ulcer disease or patients using concurrent nonsteroidal anti-inflammatory drugs (NSAIDS). (Galantamin etiketi, Uyarılar ve önlemler)

Gastrointestinal Conditions Through their primary action, cholinomimetics may be expected to increase gastric acid secretion due to increased cholinergic activity. (Galantamin etiketi, Uyarılar ve önlemler)

Therefore, patients should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those with an increased risk for developing ulcers, e.g., those with a history of ulcer disease or patients using concurrent nonsteroidal anti-inflammatory drugs (NSAIDS). (Galantamin etiketi, Uyarılar ve önlemler)

Therefore, patients should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those with an increased risk for developing ulcers, e.g., those with a history of ulcer disease or patients using concurrent nonsteroidal anti-inflammatory drugs (NSAIDS). (Galantamin etiketi, Uyarılar ve önlemler)

Therefore, patients should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those with an increased risk for developing ulcers, e.g., those with a history of ulcer disease or patients using concurrent nonsteroidal anti-inflammatory drugs (NSAIDS). (Galantamin etiketi, Uyarılar ve önlemler)

Therefore, patients should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those with an increased risk for developing ulcers, e.g., those with a history of ulcer disease or patients using concurrent nonsteroidal anti-inflammatory drugs (NSAIDS). (Galantamin etiketi, Uyarılar ve önlemler)

Therefore, patients should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those with an increased risk for developing ulcers, e.g., those with a history of ulcer disease or patients using concurrent nonsteroidal anti-inflammatory drugs (NSAIDS). (Galantamin etiketi, Uyarılar ve önlemler)

Dicyclomine hydrochloride should be given to patients with myasthenia gravis only to reduce adverse muscarinic effects of an anticholinesterase (5.4) (Disikloverin etiketi, Uyarılar ve önlemler)

Anticholinesterases: BREVIBLOC prolonged the duration of succinylcholine-induced neuromuscular blockade and moderately prolonged clinical duration and recovery index of mivacurium. (Esmolol etiketi, İlaç etkileşimleri)

Therefore, patients should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those with an increased risk for developing ulcers, e.g., those with a history of ulcer disease or patients using concurrent nonsteroidal anti-inflammatory drugs (NSAIDS). (Galantamin etiketi, Uyarılar ve önlemler)

Therefore, patients should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those with an increased risk for developing ulcers, e.g., those with a history of ulcer disease or patients using concurrent nonsteroidal anti-inflammatory drugs (NSAIDS). (Galantamin etiketi, Uyarılar ve önlemler)

In case of simultaneous administration of other cholinesterase inhibitors (e.g. medicines for the treatment of dementia), caution should be exercised because of the potentiating effect. (Fizostigmin etiketi, İlaç etkileşimleri)

Therefore, patients should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those with an increased risk for developing ulcers, e.g., those with a history of ulcer disease or patients using concurrent nonsteroidal anti-inflammatory drugs (NSAIDS). (Galantamin etiketi, Uyarılar ve önlemler)

Therefore, patients should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those with an increased risk for developing ulcers, e.g., those with a history of ulcer disease or patients using concurrent nonsteroidal anti-inflammatory drugs (NSAIDS). (Galantamin etiketi, Uyarılar ve önlemler)

Therefore, patients should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those with an increased risk for developing ulcers, e.g., those with a history of ulcer disease or patients using concurrent nonsteroidal anti-inflammatory drugs (NSAIDS). (Galantamin etiketi, Uyarılar ve önlemler)

Therefore, patients should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those with an increased risk for developing ulcers, e.g., those with a history of ulcer disease or patients using concurrent nonsteroidal anti-inflammatory drugs (NSAIDS). (Galantamin etiketi, Uyarılar ve önlemler)

Therefore, patients should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those with an increased risk for developing ulcers, e.g., those with a history of ulcer disease or patients using concurrent nonsteroidal anti-inflammatory drugs (NSAIDS). (Galantamin etiketi, Uyarılar ve önlemler)

Therefore, patients should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those with an increased risk for developing ulcers, e.g., those with a history of ulcer disease or patients using concurrent nonsteroidal anti-inflammatory drugs (NSAIDS). (Galantamin etiketi, Uyarılar ve önlemler)

Therefore, patients should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those with an increased risk for developing ulcers, e.g., those with a history of ulcer disease or patients using concurrent nonsteroidal anti-inflammatory drugs (NSAIDS). (Galantamin etiketi, Uyarılar ve önlemler)

Cholinesterase inhibitors: Concomitant administration may increase the risk of cocaine toxicity. (Kokain etiketi, İlaç etkileşimleri)

Therefore, patients should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those with an increased risk for developing ulcers, e.g., those with a history of ulcer disease or patients using concurrent nonsteroidal anti-inflammatory drugs (NSAIDS). (Galantamin etiketi, Uyarılar ve önlemler)

Therefore, patients should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those with an increased risk for developing ulcers, e.g., those with a history of ulcer disease or patients using concurrent nonsteroidal anti-inflammatory drugs (NSAIDS). (Galantamin etiketi, Uyarılar ve önlemler)

Therefore, patients should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those with an increased risk for developing ulcers, e.g., those with a history of ulcer disease or patients using concurrent nonsteroidal anti-inflammatory drugs (NSAIDS). (Galantamin etiketi, Uyarılar ve önlemler)

Therefore, patients should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those with an increased risk for developing ulcers, e.g., those with a history of ulcer disease or patients using concurrent nonsteroidal anti-inflammatory drugs (NSAIDS). (Galantamin etiketi, Uyarılar ve önlemler)

Therefore, patients should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those with an increased risk for developing ulcers, e.g., those with a history of ulcer disease or patients using concurrent nonsteroidal anti-inflammatory drugs (NSAIDS). (Galantamin etiketi, Uyarılar ve önlemler)

Therefore, patients should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those with an increased risk for developing ulcers, e.g., those with a history of ulcer disease or patients using concurrent nonsteroidal anti-inflammatory drugs (NSAIDS). (Galantamin etiketi, Uyarılar ve önlemler)

Use with caution due to aggravation of symptoms: Pre-existing dementia in patients treated with cholinesterase inhibitors ( 5.2 ), Parkinson’s disease ( 5.2 ), Myasthenia gravis ( 5.3 ), and Decreased gastrointestinal motility in patients with autonomic neuropathy ( 5.4 ). (Oksibutinin etiketi, Uyarılar ve önlemler)

Therefore, patients should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those with an increased risk for developing ulcers, e.g., those with a history of ulcer disease or patients using concurrent nonsteroidal anti-inflammatory drugs (NSAIDS). (Galantamin etiketi, Uyarılar ve önlemler)

Therefore, patients should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those with an increased risk for developing ulcers, e.g., those with a history of ulcer disease or patients using concurrent nonsteroidal anti-inflammatory drugs (NSAIDS). (Galantamin etiketi, Uyarılar ve önlemler)

Gastrointestinal Conditions Through their primary action, cholinomimetics may be expected to increase gastric acid secretion due to increased cholinergic activity. (Galantamin etiketi, Uyarılar ve önlemler)

Therefore, patients should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those with an increased risk for developing ulcers, e.g., those with a history of ulcer disease or patients using concurrent nonsteroidal anti-inflammatory drugs (NSAIDS). (Galantamin etiketi, Uyarılar ve önlemler)

Myasthenia Gravis Patients with myasthenia gravis may show worsening of symptoms from PA due to its procaine-like effect on diminishing acetylcholine release at skeletal muscle motor nerve endings, so that PA administration may be hazardous without optimal adjustment of anticholinesterase medications and other precautions. (Prokainamid etiketi, Uyarılar)

Therefore, patients should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those with an increased risk for developing ulcers, e.g., those with a history of ulcer disease or patients using concurrent nonsteroidal anti-inflammatory drugs (NSAIDS). (Galantamin etiketi, Uyarılar ve önlemler)

Therefore, patients should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those with an increased risk for developing ulcers, e.g., those with a history of ulcer disease or patients using concurrent nonsteroidal anti-inflammatory drugs (NSAIDS). (Galantamin etiketi, Uyarılar ve önlemler)

Gastrointestinal Conditions Through their primary action, cholinomimetics may be expected to increase gastric acid secretion due to increased cholinergic activity. (Galantamin etiketi, Uyarılar ve önlemler)

Gastrointestinal Conditions Through their primary action, cholinomimetics may be expected to increase gastric acid secretion due to increased cholinergic activity. (Galantamin etiketi, Uyarılar ve önlemler)

Therefore, patients should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those with an increased risk for developing ulcers, e.g., those with a history of ulcer disease or patients using concurrent nonsteroidal anti-inflammatory drugs (NSAIDS). (Galantamin etiketi, Uyarılar ve önlemler)

Therefore, patients should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those with an increased risk for developing ulcers, e.g., those with a history of ulcer disease or patients using concurrent nonsteroidal anti-inflammatory drugs (NSAIDS). (Galantamin etiketi, Uyarılar ve önlemler)

When Phase II block is suspected in cases of prolonged neuromuscular blockade, positive diagnosis should be made by peripheral nerve stimulation, prior to administration of any anticholinesterase drug. (Süksinilkolin etiketi, Uyarılar ve önlemler)

Therefore, patients should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those with an increased risk for developing ulcers, e.g., those with a history of ulcer disease or patients using concurrent nonsteroidal anti-inflammatory drugs (NSAIDS). (Galantamin etiketi, Uyarılar ve önlemler)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (Galantamin etiketi, İlaç etkileşimleri)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (Galantamin etiketi, İlaç etkileşimleri)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (Galantamin etiketi, İlaç etkileşimleri)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (Galantamin etiketi, İlaç etkileşimleri)

Anesthesia Galantamine, as a cholinesterase inhibitor, is likely to exaggerate the neuromuscular blocking effects of succinylcholine-type and similar neuromuscular blocking agents during anesthesia. (Galantamin etiketi, Uyarılar ve önlemler)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (Galantamin etiketi, İlaç etkileşimleri)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (Galantamin etiketi, İlaç etkileşimleri)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (Galantamin etiketi, İlaç etkileşimleri)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (Galantamin etiketi, İlaç etkileşimleri)

Anesthesia Galantamine, as a cholinesterase inhibitor, is likely to exaggerate the neuromuscular blocking effects of succinylcholine-type and similar neuromuscular blocking agents during anesthesia. (Galantamin etiketi, Uyarılar ve önlemler)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (Galantamin etiketi, İlaç etkileşimleri)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (Galantamin etiketi, İlaç etkileşimleri)

Anticholinesterases Concomitant use of anticholinesterase agents and corticosteroids may produce severe weakness in patients with myasthenia gravis. (Deksametazon etiketi, İlaç etkileşimleri)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (Galantamin etiketi, İlaç etkileşimleri)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (Galantamin etiketi, İlaç etkileşimleri)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (Galantamin etiketi, İlaç etkileşimleri)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (Galantamin etiketi, İlaç etkileşimleri)

Cholinesterase Inhibitors Dipyridamole may counteract the anticholinesterase effect of cholinesterase inhibitors, thereby potentially aggravating myasthenia gravis. (Dipiridamol etiketi, İlaç etkileşimleri)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (Galantamin etiketi, İlaç etkileşimleri)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (Galantamin etiketi, İlaç etkileşimleri)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (Galantamin etiketi, İlaç etkileşimleri)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (Galantamin etiketi, İlaç etkileşimleri)

Synergistic effect expected when given concurrently with succinylcholine, other cholinesterase inhibitors, similar neuromuscular blocking agents, or cholinergic agonists ( 7.2 ) (Galantamin etiketi, İlaç etkileşimleri)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (Galantamin etiketi, İlaç etkileşimleri)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (Galantamin etiketi, İlaç etkileşimleri)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (Galantamin etiketi, İlaç etkileşimleri)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (Galantamin etiketi, İlaç etkileşimleri)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (Galantamin etiketi, İlaç etkileşimleri)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (Galantamin etiketi, İlaç etkileşimleri)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (Galantamin etiketi, İlaç etkileşimleri)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (Galantamin etiketi, İlaç etkileşimleri)

Anesthesia Galantamine, as a cholinesterase inhibitor, is likely to exaggerate the neuromuscular blocking effects of succinylcholine-type and similar neuromuscular blocking agents during anesthesia. (Galantamin etiketi, Uyarılar ve önlemler)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (Galantamin etiketi, İlaç etkileşimleri)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (Galantamin etiketi, İlaç etkileşimleri)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (Galantamin etiketi, İlaç etkileşimleri)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (Galantamin etiketi, İlaç etkileşimleri)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (Galantamin etiketi, İlaç etkileşimleri)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (Galantamin etiketi, İlaç etkileşimleri)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (Galantamin etiketi, İlaç etkileşimleri)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (Galantamin etiketi, İlaç etkileşimleri)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (Galantamin etiketi, İlaç etkileşimleri)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (Galantamin etiketi, İlaç etkileşimleri)

Synergistic effect expected when given concurrently with succinylcholine, other cholinesterase inhibitors, similar neuromuscular blocking agents, or cholinergic agonists ( 7.2 ) (Galantamin etiketi, İlaç etkileşimleri)

Anticholinesterases : Concomitant use of anticholinesterase agents and corticosteroids may produce severe weakness in patients with myasthenia gravis. (Metilprednizolon etiketi, İlaç etkileşimleri)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (Galantamin etiketi, İlaç etkileşimleri)

Synergistic effect expected when given concurrently with succinylcholine, other cholinesterase inhibitors, similar neuromuscular blocking agents, or cholinergic agonists ( 7.2 ) (Galantamin etiketi, İlaç etkileşimleri)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (Galantamin etiketi, İlaç etkileşimleri)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (Galantamin etiketi, İlaç etkileşimleri)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (Galantamin etiketi, İlaç etkileşimleri)

Anesthesia Galantamine, as a cholinesterase inhibitor, is likely to exaggerate the neuromuscular blocking effects of succinylcholine-type and similar neuromuscular blocking agents during anesthesia. (Galantamin etiketi, Uyarılar ve önlemler)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (Galantamin etiketi, İlaç etkileşimleri)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (Galantamin etiketi, İlaç etkileşimleri)

Anticholinesterase agents: Concomitant use of anticholinesterase agents and corticosteroids may produce severe weakness in patients with myasthenia gravis. (Prednizolon etiketi, İlaç etkileşimleri)

Anticholinesterase Agents Concomitant use of anticholinesterase agents and corticosteroids may produce severe weakness in patients with myasthenia gravis. (Prednizon etiketi, İlaç etkileşimleri)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (Galantamin etiketi, İlaç etkileşimleri)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (Galantamin etiketi, İlaç etkileşimleri)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (Galantamin etiketi, İlaç etkileşimleri)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (Galantamin etiketi, İlaç etkileşimleri)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (Galantamin etiketi, İlaç etkileşimleri)

Synergistic effect expected when given concurrently with succinylcholine, other cholinesterase inhibitors, similar neuromuscular blocking agents, or cholinergic agonists ( 7.2 ) (Galantamin etiketi, İlaç etkileşimleri)

Anesthesia Galantamine, as a cholinesterase inhibitor, is likely to exaggerate the neuromuscular blocking effects of succinylcholine-type and similar neuromuscular blocking agents during anesthesia. (Galantamin etiketi, Uyarılar ve önlemler)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (Galantamin etiketi, İlaç etkileşimleri)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (Galantamin etiketi, İlaç etkileşimleri)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (Galantamin etiketi, İlaç etkileşimleri)

Anesthesia Galantamine, as a cholinesterase inhibitor, is likely to exaggerate the neuromuscular blocking effects of succinylcholine-type and similar neuromuscular blocking agents during anesthesia. (Galantamin etiketi, Uyarılar ve önlemler)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (Galantamin etiketi, İlaç etkileşimleri)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (Galantamin etiketi, İlaç etkileşimleri)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (Galantamin etiketi, İlaç etkileşimleri)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (Galantamin etiketi, İlaç etkileşimleri)

Anticholinesterases: Concomitant use of anticholinesterase agents and corticosteroids may produce severe weakness in patients with myasthenia gravis. (Triamsinolon etiketi, İlaç etkileşimleri)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (Galantamin etiketi, İlaç etkileşimleri)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (Galantamin etiketi, İlaç etkileşimleri)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (Galantamin etiketi, İlaç etkileşimleri)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (Galantamin etiketi, İlaç etkileşimleri)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (Galantamin etiketi, İlaç etkileşimleri)

Anesthesia Galantamine, as a cholinesterase inhibitor, is likely to exaggerate the neuromuscular blocking effects of succinylcholine-type and similar neuromuscular blocking agents during anesthesia. (Galantamin etiketi, Uyarılar ve önlemler)

In drug interaction studies, oral RISPERDAL did not significantly affect the pharmacokinetics of donepezil and galantamine, which are metabolized by CYP 2D6. (Risperidon etiketi, İlaç etkileşimleri)